


 The logo for the journal Radiology, featuring the word "Radiology" in a blue serif font inside a light gray rectangular box.

**Thrombus Distribution in Vaccine-induced immune
thrombotic thrombocytopenia after ChAdOx1 nCov-19
Vaccination**

Journal:	<i>Radiology</i>
Manuscript ID	RAD-22-0365.R3
Manuscript Type:	Case Series
Manuscript Categorization Terms:	Interventional-Vascular < 2. MODALITIES/TECHNIQUES, CT-Angiography < 2. MODALITIES/TECHNIQUES, MR-Imaging < 2. MODALITIES/TECHNIQUES, Thrombolysis < 3. PROCEDURES, Abdomen/GI < 4. AREAS/SYSTEMS, CNS < 4. AREAS/SYSTEMS, Vascular < 4. AREAS/SYSTEMS, Thorax < 4. AREAS/SYSTEMS, Veins < 5. STRUCTURES, Hematologic Diseases < 6. TOPICS

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11 **Thrombus Distribution in Vaccine-induced immune thrombotic thrombocytopenia after**
12 **ChAdOx1 nCov-19 Vaccination**

13 Priya Rogers MBBS ^{1,9}
14 Ieuan Walker MBBS ¹
15 Jason Yeung MBBS ^{2,9}
16 Abeera Khan MBBS ^{3,9}
17 Anmol Gangi MBChB ^{3,9}
18 Behnaz Mobashwera MBBS ³
19 Robert Ayto MBBS ³
20 Ali Shah FRCR ^{4 8}
21 Joannes Hermans MBBS ⁴
22 Andrew Murchison BMBCh ^{5,9}
23 Matthew Benger MBBS ^{6,9}
24 Sean Apap Mangion MSc ⁶
25 Puja R Mehta MBBChir ⁶
26 Laszlo Sztriha PhD ⁶
27 Simrit Ghatorae MB ChB ⁷
28 Brian Craven MBBCh ²
29 Marie Scully MD ²
30 Timothy Bray MBBChir PhD ^{2,8,9}
31 Margaret Hall-Craggs MBBS MD ^{2,8,9}
32 Conrad Von Stempel MBBS ²

33 “for the RADIANT Group” ⁸

34 **Affiliations**

- 35 1. Addenbrooke’s Hospital, Cambridge.
- 36 2. University College London Hospital, London.
- 37 3. Queen Alexandra Hospital, Portsmouth.
- 38 4. Nottingham University Hospitals NHS Foundation Trust, Nottingham.
- 39 5. Oxford University Hospitals NHS Foundation Trust, Oxford.
- 40 6. King’s College Hospital, London.
- 41 7. Queen Elizabeth University Hospital, Glasgow.
- 42 8. Centre for Medical Imaging, University College London
- 43 9. Radiology Academic Network for Trainees (RADIANT), UK

44 **Corresponding author:**

45 Dr Conrad von Stempel
46 Conrad.vonstempel@nhs.net
47 Radiology Department UCH Podium 2
48 235 Euston Road
49 London
50 NW12BU

51 **Manuscript type:**

52 Case series

53 **Word count:**

54 Abstract: 91 words
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 Introduction to discussion: 1677 words

11
12 Data generated or analyzed during the study are available from the corresponding author by
13 request.

14
15 **No funding was received for this research.**

16
17 TJPB was funded by an NIHR Clinical Lectureship (CL-2019-18-001). MHC is supported by the
18 National Institute for Health Research (NIHR) Biomedical Research Centre (BRC). UCLH/UCL
19 receives funding from the UK Department of Health's the NIHR BRC funding scheme. EPSRC:
20 <https://epsrc.ukri.org> National Institute of Health Research: <https://www.nihr.ac.uk> The
21 funders had no role in study design, data collection and analysis, decision to publish, or
22 preparation of the manuscript.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Commented [PR1]: E1.2

In response to *Editor's comment 2:*

Edited in line with Radiology formatting guidelines

Title

Thrombus Distribution in Vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1
nCov-19 Vaccination

Abbreviations

VITT – Vaccine-induced immune thrombotic thrombocytopenia

CVST - Cerebral venous sinus thrombosis

PVT – Portomesenteric venous thrombosis

PE - Pulmonary embolism

Summary statement

MRI, CT and ultrasound detected occult sites of thrombosis in a large majority of patients presenting with vaccine-induced thrombocytopenia and thrombosis after receiving their first dose of the ChAdOx1 nCov-19 vaccine.

Key results

1. Of the 40 patients with confirmed vaccine-induced thrombocytopenia and thrombosis (VITT), 80% (n=32) developed symptoms within 14 days of receiving their first dose of the ChAdOx1 nCov-19 vaccine, and 20% (n=8) within 14-28 days.
2. 83% of those who underwent additional imaging (25 of 30) had occult sites of thrombosis, while 30% (12 of 40) had extension of the primary thrombus.
3. 20% (8 of 40) of the patients with confirmed VITT died.

Abstract

This case series reports 40 patients (median age, 41 years [interquartile range (IQR) 32- 52, 22 men) with confirmed vaccine-induced immune thrombotic thrombocytopenia after administration of their first ChAdOx1 nCov-19 (AstraZeneca) vaccine: 80% (n=32) developed symptoms within the first 14 days and 20% (n=8) within 14-28 days. The location and extent of thrombi were evaluated using CT, MRI and ultrasound. Of the 40, 73% (n=29) presented with neurological symptoms and had confirmed cerebral venous sinus thrombosis, 30% (n=12) had extension of their primary thrombus, and 20% (n=8) died. 83% of those who underwent additional imaging (25 of 30) had occult thrombosis.

Introduction

Vaccination strategies have been at the forefront of controlling the Covid-19 pandemic ¹. An association between vaccine-induced immune thrombotic thrombocytopenia (VITT) and one of these vaccines, the ChAdOx1 nCov-19 vaccine (AstraZeneca), is now recognized ²⁻⁵. VITT is related to auto-antibody generation against platelet factor four (PF4), with all confirmed patients exhibiting high titers²⁻⁴; patients phenotypically demonstrate thrombosis.

The management of VITT follows limited evidence: guidelines suggest treating the thrombosis with non-heparin anticoagulants and possible fibrinogen replacement therapy ⁶ or interventional techniques ⁷⁻¹⁰, and managing the immune response with intravenous immunoglobulins and possibly corticosteroids, plasma exchange or rituximab⁶.

The anatomical location and frequency of thrombosis has not previously been well established in the literature on VITT. The role of imaging in VITT is to diagnose thrombosis and complications, and to guide intervention. International guidance suggests targeting imaging to the localizing symptoms¹⁰⁻¹⁵. However, no guidance specifically recommends whole-body imaging to assess for occult sites of thrombosis despite the high likelihood of developing multiple sites of thrombosis. Thus, we investigated the frequency and location of thrombosis in each vascular system using CT, MRI and ultrasound to identify additional sites of thrombus in a UK-wide sample of patients with confirmed VITT.

Materials and Methods

UK Health Research Authority confirmed that this multicenter retrospective observational study, using routine anonymous patient data, could proceed without the need for review by an ethics committee.

Thirty-two radiology centers identified through the national collaborative Radiology Academic Network for Trainees were invited from the United Kingdom; seven of these contributed to this study. All patients with confirmed VITT between February 3, 2021 and May 12, 2021 that met the inclusion criteria were included.

The inclusion criteria were presentation within 28 days following administration of the ChAdOx1 nCov-19 vaccine, presence of anti-PF4 antibodies, thrombocytopenia $<150 \times 10^9/\text{liter}$ and new radiologically confirmed thrombosis on at least one contrast-enhanced CT scan. The exclusion criteria were a history of thrombophilia, a positive Covid-19 PCR serological test, and if PF4 antibody testing or imaging information was unavailable.

Patients were identified by a search of local hematology databases, anti-PF4 testing and cross-referencing with imaging on local Picture Archiving and Communication Systems (PACS). The electronic health record for each included case was reviewed to collect the demographic data, clinical information, laboratory results and outcomes (supplemental table). Patient demographics, clinical, biochemical and imaging information were recorded on standardized data collection sheets. Imaging was reviewed locally by consultant radiologists or senior radiology trainees (with at least 4 years of experience in cross-sectional imaging) unblinded.

CT, US, and MRI were performed according to local hospital protocols (table 1a). Readers commented on thrombus in the following vascular systems, to a subsegmental level where possible (table 1b): a) cerebral venous sinus thrombosis, b) systemic deep venous thrombosis (lower limb deep vein thrombosis, inferior and superior venae cavae, hepatic, renal and adrenal veins), c)

1
2
3 portomesenteric venous thrombosis (portal, superior and inferior mesenteric and splenic veins), d)
4
5 systemic arterial thrombosis (including intracranial and visceral arterial thrombosis), and e)
6
7 pulmonary embolism (PE).
8
9

10
11
12 Images were stratified into three categories: cerebral imaging (head CT, brain MRI and venogram
13
14 CT), whole-body imaging (chest, abdomen and pelvis CT) and partial-body imaging (any patient that
15
16 did not have a complete chest, abdomen and pelvis CT examination, which included focused
17
18 ultrasound assessment).
19

20 21 22 23 *Statistical Analysis*

24
25 Descriptive statistics were used to describe proportions of scans and/or patients with thrombus at
26
27 each anatomical site, using Microsoft Excel version 16.60. Continuous variables were not normally
28
29 distributed and are described as medians with interquartile (IQR) and full range, whereas categorical
30
31 variables are described as a number and/or percentage.
32
33
34
35

36 **Results**

37 38 *Patient Characteristics*

39
40
41 Between February 3, 2021 and May 12, 2021, 40 patients met inclusion criteria from 7 different
42
43 centers across the United Kingdom (supplemental table).
44

45
46 The median age was 41 years [interquartile range (IQR) 32- 52, range 21 to 66]: 22 of 40 were men
47
48 (55%). 32 of 40 patients (80%) developed symptoms within 14 days of their first ChAdOx1 nCov-19
49
50 vaccine, and 8 of 40 patients (20%) presented 14-28 days post-vaccine. None of the patients had
51
52 received their second vaccine dose at presentation (supplemental table).
53
54
55

56 57 *Sites and multiplicity of thrombus across all patients*

58
59
60

1
2
3 At presentation, 10 of 40 patients (25%) underwent targeted imaging based on symptoms alone; 30
4
5 of 40 patients (75%) underwent additional imaging as detailed below (table 1a). Whole-body
6
7 imaging with contrast-enhanced axial CT was performed in 26 of 40 patients (65%), and partial-body
8
9 imaging (defined in methods) in 4 of 40 (10%) within 48 hours of admission.
10
11
12
13

14 Further imaging during the study period identified additional sites of thrombosis in a total of 25 of
15
16 the 30 patients who underwent additional imaging (83%). The commonest additional sites were a
17
18 combination of cerebral venous sinus thrombosis and pulmonary embolism in 16 of 40 patients
19
20 (40%), or cerebral venous sinus thrombosis and portomesenteric venous thrombosis in 9 of 40
21
22 patients (23%). The total numbers of thromboses identified in each vascular system across all 40
23
24 patients were: 34 of 40 cerebral venous sinus thrombosis; 17 of 40 pulmonary embolism; 10 of 40
25
26 portomesenteric venous thrombosis; 11 of 40 with deep venous thrombosis, and 8 of 40 with
27
28 systemic arterial thrombosis.
29
30
31
32
33
34
35

36 *Analysis by mode of presentation*

37
38 29 of 40 patients (73%) presented with predominantly neurological symptoms (fig 1-3) including
39
40 severe headache, blurred vision, seizure or collapse. In all 29 patients, CT or MR venogram identified
41
42 cerebral venous sinus thrombosis (table 1b). In 15 of 29 of these patients (52%), intracranial
43
44 hemorrhage was associated, which was bilateral in 3 of 15 patients (20%). Further imaging was
45
46 completed in 20 of 29 patients (69%) with whole-body imaging in 17 and partial imaging in 3. Of the
47
48 20 of 29 patients who received further imaging, additional site(s) of thrombus were identified in 17
49
50 patients (85%): pulmonary embolism in 12 (60%), portomesenteric venous thrombosis in 5 (25%),
51
52 deep venous thrombosis in 6 (30%), and systemic arterial thrombosis in 4 (20%).
53
54
55
56
57
58
59
60

1
2
3 6 of 40 patients (15%) presented with thoracic symptoms of dyspnea, cough, chest pain or
4
5 hemoptysis. In all 6 patients, pulmonary embolism (PE) or intracardiac or coronary thrombus was
6
7 confirmed (table 1b). Further imaging was performed in 5 of 6 (83%) of these patients. Of these 5, 1
8
9 (20%) had solitary PE, 3 (60%) had additional cerebral venous sinus thrombosis, and 3 (60%) had
10
11 additional intra-abdominal thrombosis (portomesenteric venous thrombosis and deep venous
12
13 thrombosis).
14
15

16
17
18 4 of 40 patients (10%) presented with gastrointestinal symptoms including abdominal pain,
19
20 vomiting, and rectal bleeding. In all 4 of these patients, an intra-abdominal thrombosis was found
21
22 (table 1b): 2 with portomesenteric venous thrombosis (50%) and 2 with adrenal and renal vein
23
24 thrombosis (50%). Further imaging in these 4 patients demonstrated 2 patients (2 of 4) had cerebral
25
26 venous sinus thrombosis (50%), 1 pulmonary embolism (25%), and 1 combined cerebral venous
27
28 sinus thrombosis and intracranial arterial thrombosis (25%).
29
30
31

32
33
34 In all patients with occult portomesenteric venous thrombosis and pulmonary embolism, clinical
35
36 monitoring was undertaken and serial imaging was indicated if there were clinical signs of
37
38 developing venous bowel ischemia or right-heart strain.
39
40

41 42 43 *Treatment:*

44
45 Treatments consisted of anticoagulation, plasma exchange, steroids and intravenous
46
47 immunoglobulins. Of 40 patients, 7 (18%) underwent platelet transfusion and 1 patient (2.5%) was
48
49 treated with eltrombopag (Revolade 25 mg tablets, Novartis Pharmaceuticals UK Ltd). In 2 patients,
50
51 (5%) of splanchnic venous occlusion and small bowel compromise, patients were transferred to
52
53 tertiary hepatobiliary centers for further management (supplemental table).
54
55
56

57 58 59 *Patient outcomes:* 60

1
2
3 Median follow-up was 44 days; during this period 8 of 40 patients (20%) had died, all of brain
4 herniation secondary to large volume cerebral edema. 12 of 40 patients (30%) had clinical
5 deterioration and underwent repeat imaging. In 8 of these 12 patients (67%) this showed extension
6 of intracranial thrombus, in 4 of these 12 patients (33%) there was extension of thrombus in a
7 second vascular system. Of the 4 patients with progressing thrombus, 2 of the 4 (50%) had died of
8 complications of VITT.
9
10
11
12
13
14
15
16
17
18
19
20

21 Discussion

22
23 International guidance suggests symptom-specific imaging for vaccine-induced immune thrombotic
24 thrombocytopenia, but there remains a paucity of data on the prevalence of multi-site thrombosis
25 and the implications of this on management. This is the largest study to date of patients with
26 vaccine-induced immune thrombotic thrombocytopenia with whole-body imaging and multi-system
27 thrombosis.
28
29
30
31
32
33
34
35
36

37 In the 25 of 40 patients undergoing additional imaging (imaging in addition to that focused on the
38 presenting site), a very high proportion (83%) of patients had additional-site thrombosis. This is
39 much higher than the reported diagnoses of VITT where multi-site thrombosis was seen in 27-50% of
40 patients, likely reflecting that fact that many of these studies did not perform comprehensive whole-
41 body imaging ^{2-4,16-20}. In our study, progressive thrombosis was observed within the first seven days
42 after presentation in a substantial proportion of patients. The overall mortality in our study sample
43 was 20%, and mortality in those with confirmed progressive thrombosis this was 50%. These findings
44 emphasize that VITT is a multisystem disorder and suggest that whole-body contrast-enhanced
45 imaging is likely to identify further thrombosis.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Additional imaging was performed in 30 of 40 (75%) patients, mostly with CT Pulmonary Angiogram
4 or CT Abdomen and Pelvis . For example, in neurologically unwell patients with VITT and cerebral
5 venous sinus thrombosis, signs and symptoms of developing splanchnic venous thrombosis may be
6 asymptomatic. Whole-body imaging can identify patients who require early referral to specialist
7 vascular or hepatobiliary centers for catheter-directed thrombolysis or transjugular intrahepatic
8 portosystemic shunting, for instance. ^{10,21}
9
10
11
12
13
14
15
16
17
18

19 A strength of our study was the involvement of the Radiology Academic Network for Trainees
20 network to identify a large number of patients across the United Kingdom. The retrospective study
21 design imposed some limitations: patients were excluded if specific hematological (PF4 antibody)
22 testing or imaging information was unavailable and inclusion was limited to symptomatic patients
23 presenting to hospital. To date, imaging patients for asymptomatic thrombosis in vaccine-induced
24 immune thrombotic thrombocytopenia is not within routine clinical practice in the United Kingdom.
25
26 It is therefore possible that in instances of limited whole-body imaging, the number of occult
27 thromboses may be considerably higher than reported.
28
29
30
31
32
33
34
35
36
37
38

39 **Conclusion**

40
41 In conclusion, patients with vaccine-induced immune thrombotic thrombocytopenia are likely to
42 present with multiple sites of thrombosis, most frequently cerebral venous sinus thrombosis in
43 combination with pulmonary embolism and portomesenteric venous thrombosis. Whole-body
44 imaging with contrast-enhanced CT imaging can identify occult thrombosis.
45
46
47
48
49
50
51

52 **Acknowledgements**

53
54 None.
55
56
57
58

59 **References**

- 1
2
3 1. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black
4 Patients and White Patients with Covid-19. *N Engl J Med.* 2020;382(26).
5
6 doi:10.1056/nejmsa2011686
7
- 8
9 2. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic
10 Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N Engl J Med.* 2021;384(22):2092-
11 2101. doi:10.1056/nejmoa2104840
12
13
14
- 15 3. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after ChAdOx1
16 nCoV-19 Vaccination. *N Engl J Med.* 2021;384(22). doi:10.1056/nejmoa2104882
17
18
19
- 20 4. Scully M, Singh D, Lown R, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1
21 nCoV-19 Vaccination. *N Engl J Med.* 2021;384(23). doi:10.1056/nejmoa2105385
22
23
24
- 25 5. MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca
26 and extremely rare, unlikely to occur blood clots.
27
28 [https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-](https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots)
29 [between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots.](https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots)
30
31 Accessed November 1, 2021.
32
33
- 34 6. B. Bussel, MD; Jean M. Connors, MD; Douglas B. Cines, MD; Cynthia E. Dunbar, MD; Laura C.
35 Michaelis, MD; Lisa Baumann Kreuziger, MD; Agnes Y. Y. Lee, MD, MSc; and Ingrid Pabinger-
36 Fasching M. Thrombosis with Thrombocytopenia Syndrome.
37
38 [https://www.hematology.org/covid-19/vaccine-induced-immune-](https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia)
39 [thrombotic-](https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia)
40 [thrombotic-thrombocytopenia.](https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia) [https://www.hematology.org/covid-19/vaccine-induced-immune-](https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia)
41 [thrombotic-thrombocytopenia.](https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia) Published 2021. Accessed November 1, 2021.
42
43
44
- 45 7. Padley GJ, Desai SS, Weaver C, Price LC, Arachchillage DJ, Ridge CA. Catheter-Directed
46 Thrombolysis in a Patient with Severe COVID-19 Pneumonia on Extracorporeal Membrane
47 Oxygenation. *Semin Thromb Hemost.* 2020;46(7):850-852. doi:10.1055/s-0040-1715457
48
49
50
- 51 8. Vlachou M, Drebes A, Candilio L, et al. Pulmonary thrombosis in Covid-19: before, during and
52 after hospital admission. *J Thromb Thrombolysis.* 2021;51(4):978-984. doi:10.1007/s11239-
53
54
55
56
57
58
59
60

- 1
2
3 020-02370-7
4
5
6 9. Dhoot R, Kansal A, Handran C, et al. Thrombocytopenia and splanchnic thrombosis after
7 Ad26.COVS.2.S vaccination successfully treated with transjugular intrahepatic portosystemic
8 shunting and thrombectomy. *Am J Hematol*. 2021;96(9). doi:10.1002/ajh.26258
9
10
11
12 10. Intercollegiate Multidisciplinary Guidance for Clinicians. *Diagnosis and Management of*
13 *Gastrointestinal Manifestations of Vaccine Induced Thrombosis and Thrombocytopenia (VITT)*
14 *Syndrome. Intercollegiate Multidisciplinary Guidance for Clinicians.*; 2021.
15
16
17
18 11. THANZ. THANZ Multidisciplinary VITT guidelines for doctors.
19 <https://www.thanz.org.au/news/vitt-multidisciplinary-guideline-for-doctors>. Accessed
20 November 1, 2021.
21
22
23
24
25 12. NICE. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis
26 (VITT). Published: 29 July 2021. www.nice.org.uk/guidance/ng200. Published 2021. Accessed
27 November 1, 2021.
28
29
30
31
32 13. ISTH. ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine- Induced Immune
33 Thrombotic Thrombocytopenia (Updated 20 April , 2021).
34 <https://www.isth.org/news/559981/>. Published 2021. Accessed November 1, 2021.
35
36
37
38
39 14. BSNR. Management of patients presenting to the Emergency Department/ Acute Medicine
40 with symptoms 5-42 days post Astra Zeneca vaccine.
41 [https://rcpsg.ac.uk/documents/publications/covid-19/1749-ed-am-pathway-vaccine-](https://rcpsg.ac.uk/documents/publications/covid-19/1749-ed-am-pathway-vaccine-concerns-updated-250521/file)
42 [concerns-updated-250521/file](https://rcpsg.ac.uk/documents/publications/covid-19/1749-ed-am-pathway-vaccine-concerns-updated-250521/file). Published 2021. Accessed November 1, 2021.
43
44
45
46
47 15. Greinacher A, Langer F, Makris M, et al. Vaccine-induced immune thrombotic
48 thrombocytopenia (VITT): Update on diagnosis and management considering different
49 resources. *J Thromb Haemost*. 2022;20(1):149-156. doi:10.1111/jth.15572
50
51
52
53
54 16. Bjørnstad-Tuveng TH, Rudjord A, Anker P. Fatal cerebral haemorrhage after COVID-19
55 vaccine. *Tidsskr Nor Laegeforen*. 2021;141. doi:10.4045/tidsskr.21.0312
56
57
58
59 17. Tobaiqy M, Elkout H, Maclure K. Analysis of thrombotic adverse reactions of covid-19
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- astrazeneca vaccine reported to eudravigilance database. *Vaccines*. 2021;9(4).
doi:10.3390/vaccines9040393
18. Garnier M, Curado A, Billoir P, Barbay V, Demeyere M, Dacher JN. Imaging of
Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia.
Diagn Interv Imaging. 2021;102(10). doi:10.1016/j.diii.2021.04.005
19. Gangi A, Mobashwera B, Ganczakowski M, Ayto R. Imaging and Hematologic Findings in
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) Vaccination.
Radiology. 2022;302(2):319-325. doi:10.1148/radiol.2021211546
20. Perry RJ, Tamborska A, Singh B, et al. Cerebral venous thrombosis after vaccination against
COVID-19 in the UK: a multicentre cohort study. *Lancet*. 2021;398(10306):1147-1156.
doi:10.1016/S0140-6736(21)01608-1
21. Furfaro D, Stephens RS, Streiff MB, Brower R. Catheter-directed thrombolysis for
intermediate-risk pulmonary embolism. *Ann Am Thorac Soc*. 2018;15(2).
doi:10.1513/AnnalsATS.201706-467FR

Table 1a: Imaging modality within 48 hours of admission in relationship to presenting symptoms.

Presenting Symptom	Number of patients	CT head + CT/ MRI venogram	CT pulmonary angiogram	CT Abdomen / Pelvis with contrast	CT Chest Abdomen / Pelvis with Contrast/CT aortogram	MRI Abdomen with contrast	US duplex abdomen	US duplex peripheral veins
Neurological	29	29	9	6	9	0	2	2
GI	4	4	2	2	2	1	0	0
Chest	6	5	4	1	3	0	1	0
Other*	1	1	0	0	1	0	0	0
Total	40	39	15	9	15	1	1	1

*other: pyrexia and night sweats

Table 1b: Site of vascular thrombus after ChAdOx1 nCov-19 Vaccination in relationship to presenting symptom

Presenting Symptom	Number of patients	Pulmonary embolism	Portosystemic venous thrombosis	Cerebral venous sinus thrombosis	Deep vein thrombosis	Systemic arterial thrombosis
Neurological	29	12	5	29	6	4
GI	4	1	2	2	3	1
Chest	6	4	2	3	1	3
Other	1	1	1	0	0	0
Total	40	18	10	34	10	8

Supplemental Table: Demographic data, presenting symptoms, imaging modalities, laboratory results and outcomes of each patient with vaccine-induced immune thrombotic thrombocytopenia.

Sex	Age at presentation	Vaccine to symptoms (days)	Presenting symptoms	Relevant medical history	Thrombus	Treatment	Platelet Nadir (10 ⁹ /liter)	D-dimer (DDU)	Outcome
M	66	12	Abdominal pain	Diabetes, DVT, MG	DVT, PE, adrenal haemorrhage	LMWH, DOAC	15	10388	Alive
M	27	11	Headache	NA	CVST, ICH	DOAC, argatroban	37	NA	Died
M	32	21	Headache, vomiting	NA	CVST, ICH	LMWH, DOAC	87	NA	Alive
F	57	17	Headache, confusion	NA	CVST, ICH	DOAC	173	4985	Alive
F	64	14	Headache, confusion	Alcoholic liver disease	ICH, PE, SAT (aorta, superior mesenteric artery, cerebellar infarct)	LMWH	51	NA	Alive
M	53	10	Chest, left arm pain	Hypertension	CVST, SAT (left ventricle)	Platelet transfusion	19	10836	Died
M	64	14	Shortness of breath	NA	Aortic thrombus, SAT (aorta, renal artery, subclavian artery)	DOAC, argatroban	46	NA	Died
M	39	9	Headache	NA	CVST, ICH	LMWH	31	10316	Alive
M	59	15	Headache, expressive dysphasia and right sided neglect	NA	CVST, PE, systemic DVT (hepatic vein)	LMWH, DOAC, argatroban	58	9652	Alive
M	49	12	Vomiting, diarrhea, rectal bleeding	NA	CVST, PVT	Argatroban, IVIG, steroids, plasma exchange	13	22495	Alive
M	55	19	Headache, confusion	NA	PE, systemic DVT (hepatic vein)	IVIG and plasma exchange	121	4500	Alive

1										
2										
3	F	37	12	Headache	Cocaine use	CVST, PE, systemic DVT (common iliac vein)	UFH, IVIG, steroids, plasma exchange	9	24070	Alive
4										
5	M	22	13	Headache, hemiparesis	NA	CVST, PE, PVT	Argatroban, IVIG, steroids, plasma exchange	22	25580	Alive
6										
7										
8	M	21	2	Abdominal pain, headache	Asthma	CVST, PVT, superior vena cava thrombus	DOAC and IVIG	91	3840	Alive
9										
10	F	30	12	Headache	NA	CVST, PE, PVT, systemic DVT (splanchnic vein)	UFH IVIG, steroids, eltrombopag, platelet transfusion	14	16280	Alive
11										
12										
13	F	35	10	Headache and hemiparesis	NA	PVT, SAT (middle cerebral artery)	UFH, IVIG, plasma exchange, platelet transfusion	64	11220	Died
14										
15	F	38	14	Abdominal pain	Osteoarthritis	Renal vein thrombus, adrenal vein thrombus	DOAC, argatroban, IVIG, steroids	72	4160	Alive
16										
17	M	46	17	Chest pain	Smoker	CVST, systemic DVT (adrenal vein), SAT (right coronary artery and intracardiac thrombus)	UFH, IVIG, steroids, plasma exchange	11	24900	Alive
18										
19										
20										
21										
22	M	46	20	Headache, visual disturbance, vomiting	Essential thrombocytosis	CVST	UFH, IVIG, steroids, plasma exchange	95	17780	Alive
23										
24	F	42	12	Left-sided weakness, dysarthria, sensory inattention, hemianopia	Smoker, High body mass index	SAT (internal carotid artery and common femoral arteries)	LMWH	85	NA	Died
25										
26										
27										
28	M	32	11	Headache, blurred vision.	Hypothyroidism	SAT (internal carotid artery)	Argatroban, IVIG	6	59048	Died
29										
30	F	47	13	Hemoptysis, left-side facial rash, vomiting, left flank pain.	Depression, previous unprovoked PE, Smoker	CVST, PE, PVT, SAT (aorta, middle cerebral artery, posterior cerebral artery, brachial artery)	Fondaparinux, argatroban, IVIG	10	20000	Died
31										
32										
33										
34	M	29	11	Headache, photophobia	Mild learning difficulties	CVST	Fondaparinux, argatroban, IVIG	45	13000	Alive
35										
36	M	51	7	Headache	NA	CVST, DVT	Fondaparinux, IVIG	55	17355	Alive
37										
38	F	48	13	Headache	Asthma	CVST, PE	Fondaparinux, DOAC, IVIG, steroids	56	43087	Alive
39										
40										
41										
42										
43										
44										
45										
46										

1										
2										
3	M	46	8	Tonic clonic seizure	NA	SAT (middle cerebral artery)	Fondaparinux, IVIG, platelet transfusion	15	7678	Alive
4										
5	M	34	11	Reduced GCS, headache, vomiting, photophobia, hemiparesis	Bipolar disorder	CVST, PE	UFH, DOAC, plasma exchange, steroids, platelet transfusion	23	37293	Alive
6										
7	F	59	14	Headache, left-hand weakness.	NA	CVST, PE, systemic DVT (hepatic vein)	DOAC, argatroban, IVIG, steroids, platelet transfusion	18	38588	Alive
8										
9	F	39	11	Headache, photophobia, nausea, foot pain.	NA	CVST	DOAC, argatroban, IVIG, steroids, platelet transfusion	43	4184	Alive
10										
11	F	23	7	Headache, photophobia, vomiting, seizure, chest pain.	NA	PE, PVT, right ventricular thrombus, adrenal haemorrhage	UFH, DOAC, argatroban, steroids,	73	17548	Alive
12										
13	M	64	14	Collapse	ORIF right ankle	PE	DOAC, argatroban, IVIG,	36	8010	Alive
14										
15	M	39	16	Pyrexia, night sweats	Bipolar disorder	PE, PVT	DOAC, argatroban, IVIG, steroids	35	42155	Alive
16										
17	F	25	6	Headache	Primary sclerosing cholangitis, migraines	CVST	UFH, IVIG, steroids, platelet transfusion	7	NA	Died
18										
19	F	40	11	Headache, confusion	Migraines	CVST	IVIG, steroids	49	8000	Alive
20										
21	M	47	7	Chest pain	Hypertension, diverticulitis	SAT (circumflex coronary artery and posterior descending coronary artery)	DOAC, plasma exchange, steroids	8	5370	Alive
22										
23	M	28	13	Headache	Cardiomyopathy, acquired polycythemia secondary to smoking	CVST	IVIG, steroids	3	5690	Alive
24										
25	F	21	28	Shortness of breath, hemoptysis, pleuritic chest pain	NA	PE	DOAC, IVIG, steroids	11	1900	Alive
26										
27										
28										
29										
30										
31										
32										
33										
34										
35										
36										
37										
38										
39										
40										
41										
42										
43										
44										
45										
46										

M	48	3	Headache, blurred vision, retro-orbital pain, abdominal pain	Depression	CVST, PVT, SAT (aorta, renal artery, internal iliac artery)	Argatroban, IVIG, steroids	18	66	Alive
M	54	11	Headache	Hiatus hernia	CVST	DOAC, IVIG, steroids	117	5420	Alive
F	26	11	Headache, neck stiffness, photophobia, nausea	NA	CVST	IVIG, steroids	42	NA	Alive

Note—CTV = CT venogram; CTA = CT angiogram; CT AP = CT abdomen and pelvis; CT CAP= CT chest, abdomen and pelvis; CT KUB = CT kidney, ureter and bladder; CTPA =

CT pulmonary angiogram

DOAC = direct oral anticoagulant; DVT = deep venous thrombosis; GCS = Glasgow Coma Scale; IVIG = intravenous immunoglobulin; LMWH = low-molecular-weight heparin; MG = myasthenia gravis; MRV = MRI venogram; ORIF = open reduction and internal fixation; PE = pulmonary embolism; UFH= unfractionated heparin

Figure legends

Figure 1: Multiple modality images in a 28-year-old woman who presented with headache and subsequent collapse. Cerebral venous sinus thrombosis was diagnosed and whole-body imaging demonstrated large volume splanchnic vein thrombosis, which was treated with a transjugular intrahepatic portosystemic shunt insertion and catheter directed thrombolysis. A) Susceptibility weighted axial brain MRI showing a thrombosed internal cerebral vein branch leading to the straight sinus (arrow). B) Unenhanced axial head CT showing hyperattenuating clot within the cortical vein and transverse sinuses (arrow) C) Coronal portal venous phase abdomen CT showing thrombosed portal and superior mesenteric veins (arrows) D) Fluoroscopic angiogram images taken from a thromboaspiration catheter (red arrow) within the partially occluded superior mesenteric vein through a transjugular intrahepatic portosystemic shunt (between the white arrow). Contrast can be seen filling some segmental superior mesenteric vein branches with several filling defects in the confluence of the portal vein. E) Photograph of the thrombus cast of the superior mesenteric vein and portal vein aspirated from the splanchnic system via the portosystemic shunt using an aspiration thrombectomy catheter (Indigo, Penumbra).

Figure 2: Images in a 64-year-old woman who presented with confusion and collapse and was diagnosed with intracranial hemorrhage associated with cerebral venous sinus thrombosis secondary to VITT. A) Axial unenhanced head CT image demonstrates a large right parietal lobe intraparenchymal hemorrhage and B) bilateral infarcts in the cerebellum confirmed on Axial brain T2-weighted MRI D) CT pulmonary angiogram coronal reformatted image shows eccentric mural thrombus within the aorta (white arrow) and large central saddle embolus (red asterisks).

1
2
3 Figure 3: Images in a 56 year old man with sudden loss of consciousness 2 weeks after vaccination
4
5 for COVID-19 and subsequently diagnosed with VITT. A) Axial contrast enhanced CT
6
7 venogram Maximum Intensity Projection shows occlusive thrombus within the left transverse
8
9 sinus (white arrow) and adjacent large volume parenchymal hemorrhage in the left parietal
10
11 lobe (red arrow). Subsequent whole body imaging was performed. B) Axial CT pulmonary
12
13 angiogram showing a segmental PE (white arrow) and peripheral upper lobe infarct (red
14
15 arrow) and in C) Coronal contrast enhanced abdominal CT showing large volume main and
16
17 right portal vein thrombosis (white arrow) and hepatic vein thrombosis (red arrow)
18
19 confirmed in D) an axial image from the same study showing hepatic vein thrombus in both
20
21 the middle and right hepatic veins.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1a: Multiple modality images from a 28-year-old female patient who presented with headache and subsequent collapse. Cerebral venous sinus thrombosis was diagnosed and whole-body imaging demonstrated large volume splanchnic vein thrombosis, which was treated with a transjugular intrahepatic portosystemic shunt insertion and catheter directed thrombolysis. A) Susceptibility weighted axial brain MRI showing a thrombosed internal cerebral vein branch leading to the straight sinus (arrow). B) Unenhanced axial head CT showing hyperattenuating clot within the cortical vein and transverse sinuses (arrow) C) Coronal portal venous phase abdomen CT showing thrombosed portal and superior mesenteric veins (arrows) D) Fluoroscopic angiogram images taken from a thromboaspiration catheter (red arrow) within the partially occluded superior mesenteric vein through a transjugular intrahepatic portosystemic shunt (between the white arrow). Contrast can be seen filling some segmental superior mesenteric vein branches with several filling defects in the confluence of the portal vein. E) Photograph of the thrombus cast of the superior mesenteric vein and portal vein aspirated from the splanchnic system via the portosystemic shunt using an aspiration thrombectomy catheter (Indigo, Penumbra).



Figure 1b: Multiple modality images from a 28-year-old female patient who presented with headache and subsequent collapse. Cerebral venous sinus thrombosis was diagnosed and whole-body imaging demonstrated large volume splanchnic vein thrombosis, which was treated with a transjugular intrahepatic portosystemic shunt insertion and catheter directed thrombolysis. A) Susceptibility weighted axial brain MRI showing a thrombosed internal cerebral vein branch leading to the straight sinus (arrow). B) Unenhanced axial head CT showing hyperattenuating clot within the cortical vein and transverse sinuses (arrow) C) Coronal portal venous phase abdomen CT showing thrombosed portal and superior mesenteric veins (arrows) D) Fluoroscopic angiogram images taken from a thromboaspiration catheter (red arrow) within the partially occluded superior mesenteric vein through a transjugular intrahepatic portosystemic shunt (between the white arrow). Contrast can be seen filling some segmental superior mesenteric vein branches with several filling defects in the confluence of the portal vein. E) Photograph of the thrombus cast of the superior mesenteric vein and portal vein aspirated from the splanchnic system via the portosystemic shunt using an aspiration thrombectomy catheter (Indigo, Penumbra).




Figure 1c: Multiple modality images from a 28-year-old female patient who presented with headache and subsequent collapse. Cerebral venous sinus thrombosis was diagnosed and whole-body imaging demonstrated large volume splanchnic vein thrombosis, which was treated with a transjugular intrahepatic portosystemic shunt insertion and catheter directed thrombolysis. A) Susceptibility weighted axial brain MRI showing a thrombosed internal cerebral vein branch leading to the straight sinus (arrow). B) Unenhanced axial head CT showing hyperattenuating clot within the cortical vein and transverse sinuses (arrow) C) Coronal portal venous phase abdomen CT showing thrombosed portal and superior mesenteric veins (arrows) D) Fluoroscopic angiogram images taken from a thromboaspiration catheter (red arrow) within the partially occluded superior mesenteric vein through a transjugular intrahepatic portosystemic shunt (between the white arrow). Contrast can be seen filling some segmental superior mesenteric vein branches with several filling defects in the confluence of the portal vein. E) Photograph of the thrombus cast of the superior mesenteric vein and portal vein aspirated from the splanchnic system via the portosystemic shunt using an aspiration thrombectomy catheter (Indigo, Penumbra).



Figure 1d: Multiple modality images from a 28-year-old female patient who presented with headache and subsequent collapse. Cerebral venous sinus thrombosis was diagnosed and whole-body imaging demonstrated large volume splanchnic vein thrombosis, which was treated with a transjugular intrahepatic portosystemic shunt insertion and catheter directed thrombolysis. A) Susceptibility weighted axial brain MRI showing a thrombosed internal cerebral vein branch leading to the straight sinus (arrow). B) Unenhanced axial head CT showing hyperattenuating clot within the cortical vein and transverse sinuses (arrow) C) Coronal portal venous phase abdomen CT showing thrombosed portal and superior mesenteric veins (arrows) D) Fluoroscopic angiogram images taken from a thromboaspiration catheter (red arrow) within the partially occluded superior mesenteric vein through a transjugular intrahepatic portosystemic shunt (between the white arrow). Contrast can be seen filling some segmental superior mesenteric vein branches with several filling defects in the confluence of the portal vein. E) Photograph of the thrombus cast of the superior mesenteric vein and portal vein aspirated from the splanchnic system via the portosystemic shunt using an aspiration thrombectomy catheter (Indigo, Penumbra).




Figure 1e: Multiple modality images from a 28-year-old female patient who presented with headache and subsequent collapse. Cerebral venous sinus thrombosis was diagnosed and whole-body imaging demonstrated large volume splanchnic vein thrombosis, which was treated with a transjugular intrahepatic portosystemic shunt insertion and catheter directed thrombolysis. A) Susceptibility weighted axial brain MRI showing a thrombosed internal cerebral vein branch leading to the straight sinus (arrow). B) Unenhanced axial head CT showing hyperattenuating clot within the cortical vein and transverse sinuses (arrow) C) Coronal portal venous phase abdomen CT showing thrombosed portal and superior mesenteric veins (arrows) D) Fluoroscopic angiogram images taken from a thromboaspiration catheter (red arrow) within the partially occluded superior mesenteric vein through a transjugular intrahepatic portosystemic shunt (between the white arrow). Contrast can be seen filling some segmental superior mesenteric vein branches with several filling defects in the confluence of the portal vein. E) Photograph of the thrombus cast of the superior mesenteric vein and portal vein aspirated from the splanchnic system via the portosystemic shunt using an aspiration thrombectomy catheter (Indigo, Penumbra).




Figure 2a: Images in a 64-year-old woman who presented with confusion and collapse and was diagnosed with intracranial hemorrhage associated with cerebral venous sinus thrombosis secondary to VITT. A) Axial unenhanced head CT image demonstrates a large right parietal lobe intraparenchymal hemorrhage and B) bilateral infarcts in the cerebellum confirmed on Axial brain T2-weighted MRI D) CT pulmonary angiogram coronal reformatted image shows eccentric mural thrombus within the aorta (white arrow) and large central saddle embolus (red asterisks).




Figure 2b: Images in a 64-year-old woman who presented with confusion and collapse and was diagnosed with intracranial hemorrhage associated with cerebral venous sinus thrombosis secondary to VITT. A) Axial unenhanced head CT image demonstrates a large right parietal lobe intraparenchymal hemorrhage and B) bilateral infarcts in the cerebellum confirmed on Axial brain T2-weighted MRI D) CT pulmonary angiogram coronal reformatted image shows eccentric mural thrombus within the aorta (white arrow) and large central saddle embolus (red asterisks).



Figure 2c: Images in a 64-year-old woman who presented with confusion and collapse and was diagnosed with intracranial hemorrhage associated with cerebral venous sinus thrombosis secondary to VITT. A) Axial unenhanced head CT image demonstrates a large right parietal lobe intraparenchymal hemorrhage and B) bilateral infarcts in the cerebellum confirmed on Axial brain T2-weighted MRI D) CT pulmonary angiogram coronal reformatted image shows eccentric mural thrombus within the aorta (white arrow) and large central saddle embolus (red asterisks).



Figure 2d: Images in a 64-year-old woman who presented with confusion and collapse and was diagnosed with intracranial hemorrhage associated with cerebral venous sinus thrombosis secondary to VITT. A) Axial unenhanced head CT image demonstrates a large right parietal lobe intraparenchymal hemorrhage and B) bilateral infarcts in the cerebellum confirmed on Axial brain T2-weighted MRI D) CT pulmonary angiogram coronal reformatted image shows eccentric mural thrombus within the aorta (white arrow) and large central saddle embolus (red asterisks).




Figure 3a: Images in a 56 year old man with sudden loss of consciousness 2 weeks after vaccination for COVID-19 and subsequently diagnosed with VITT. A) Axial contrast enhanced CT venogram Maximum Intensity Projection shows occlusive thrombus within the left transverse sinus (white arrow) and adjacent large volume parenchymal hemorrhage in the left parietal lobe (red arrow). Subsequent whole body imaging was performed. B) Axial CT pulmonary angiogram showing a segmental PE (white arrow) and peripheral upper lobe infarct (red arrow) and in C) Coronal contrast enhanced abdominal CT showing large volume main and right portal vein thrombosis (white arrow) and hepatic vein thrombosis (red arrow) confirmed in D) an axial image from the same study showing hepatic vein thrombus in both the middle and right hepatic veins.




Figure 3b: Images in a 56 year old man with sudden loss of consciousness 2 weeks after vaccination for COVID-19 and subsequently diagnosed with VITT. A) Axial contrast enhanced CT venogram Maximum Intensity Projection shows occlusive thrombus within the left transverse sinus (white arrow) and adjacent large volume parenchymal hemorrhage in the left parietal lobe (red arrow). Subsequent whole body imaging was performed. B) Axial CT pulmonary angiogram showing a segmental PE (white arrow) and peripheral upper lobe infarct (red arrow) and in C) Coronal contrast enhanced abdominal CT showing large volume main and right portal vein thrombosis (white arrow) and hepatic vein thrombosis (red arrow) confirmed in D) an axial image from the same study showing hepatic vein thrombus in both the middle and right hepatic veins.



Figure 3c: Images in a 56 year old man with sudden loss of consciousness 2 weeks after vaccination for COVID-19 and subsequently diagnosed with VITT. A) Axial contrast enhanced CT venogram Maximum Intensity Projection shows occlusive thrombus within the left transverse sinus (white arrow) and adjacent large volume parenchymal hemorrhage in the left parietal lobe (red arrow). Subsequent whole body imaging was performed. B) Axial CT pulmonary angiogram showing a segmental PE (white arrow) and peripheral upper lobe infarct (red arrow) and in C) Coronal contrast enhanced abdominal CT showing large volume main and right portal vein thrombosis (white arrow) and hepatic vein thrombosis (red arrow) confirmed in D) an axial image from the same study showing hepatic vein thrombus in both the middle and right hepatic veins.





Figure 3d: Images in a 56 year old man with sudden loss of consciousness 2 weeks after vaccination for COVID-19 and subsequently diagnosed with VITT. A) Axial contrast enhanced CT venogram Maximum Intensity Projection shows occlusive thrombus within the left transverse sinus (white arrow) and adjacent large volume parenchymal hemorrhage in the left parietal lobe (red arrow). Subsequent whole body imaging was performed. B) Axial CT pulmonary angiogram showing a segmental PE (white arrow) and peripheral upper lobe infarct (red arrow) and in C) Coronal contrast enhanced abdominal CT showing large volume main and right portal vein thrombosis (white arrow) and hepatic vein thrombosis (red arrow) confirmed in D) an axial image from the same study showing hepatic vein thrombus in both the middle and right hepatic veins.

Thrombus Distribution in Vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCov-19 Vaccination



- Of the 40 patients with confirmed vaccine-induced thrombocytopenia and thrombosis (VITT), 80% (n=32) developed symptoms within 14 days of receiving their first dose of the ChAdOx1 nCov-19 vaccine, and 20% (n=8) within 14-28 days.
- 83% of those who underwent additional imaging (25 of 30) had occult sites of thrombosis, while 30% (12 of 40) had extension of the primary thrombus.
- 20% (8 of 40) of the patients with confirmed VITT died.